MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Search

Sanofi SA

Fermé

SecteurSoins de santé

88.23 0.88

Résumé

Variation du prix de l'action

24h

Actuel

Min

87.47

Max

88.42

Chiffres clés

By Trading Economics

Revenu

1.4B

1.9B

Ventes

3B

11B

P/E

Moyenne du Secteur

17.216

51.198

BPA

1.79

Rendement du dividende

4.48

Marge bénéficiaire

17.65

Employés

82,878

EBITDA

2.2B

2.8B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+31.16% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.48%

2.40%

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-19B

111B

Ouverture précédente

87.35

Clôture précédente

88.23

Sentiment de l'Actualité

By Acuity

39%

61%

136 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Sanofi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2025, 16:05 UTC

Principaux Mouvements du Marché

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 juin 2025, 09:17 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 juin 2025, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 mai 2025, 12:02 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 mai 2025, 00:06 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 juin 2025, 13:50 UTC

Résultats
Acquisitions, Fusions, Rachats

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 juin 2025, 12:33 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 juin 2025, 10:50 UTC

Acquisitions, Fusions, Rachats

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 juin 2025, 10:05 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 juin 2025, 05:06 UTC

Acquisitions, Fusions, Rachats

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 juin 2025, 05:06 UTC

Acquisitions, Fusions, Rachats

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 juin 2025, 05:05 UTC

Acquisitions, Fusions, Rachats

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 juin 2025, 05:05 UTC

Acquisitions, Fusions, Rachats

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 juin 2025, 05:04 UTC

Acquisitions, Fusions, Rachats

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 juin 2025, 05:04 UTC

Acquisitions, Fusions, Rachats

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 juin 2025, 05:03 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Blueprint Medicines Corporation

2 juin 2025, 05:02 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Blueprint Medicines Corporation

30 mai 2025, 08:58 UTC

Actions en Tendance

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 mai 2025, 05:03 UTC

Acquisitions, Fusions, Rachats

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 mai 2025, 05:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 mai 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:23 UTC

Acquisitions, Fusions, Rachats

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Acquisitions, Fusions, Rachats

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19 mai 2025, 11:01 UTC

Market Talk

Diversified Exposure to European Banks Is Required -- Market Talk

15 mai 2025, 11:04 UTC

Market Talk
Résultats

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Comparaison

Variation de prix

Sanofi SA prévision

Objectif de Prix

By TipRanks

31.16% hausse

Prévisions sur 12 Mois

Moyen 114.266 EUR  31.16%

Haut 127 EUR

Bas 95 EUR

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

12

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

91.3 / 96.1Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

136 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.